Serum level of SALL4 in gastric cancer patients and its effect on migration of gastric cancer cells
LIU Lei1 LI Yan2 GUO Yuanbiao1
1.Department of Research Center of Experimental Medicine, the Third People′s Hospital of Chengdu (Second Affiliated Hospital, Chongqing Medical University), Sichuan Province, Chengdu 610031, China;
2.Department of Infectious Diseases, the 42 Hospital of People′s Liberation Army, Sichuan Province, Leshan 614000, China
Abstract：Objective To investigate the difference of serum SALL4 levels between gastric cancer patients and healthy people, and to explore the role of SALL4 in the progression of gastric cancer. Methods A total of 47 patients with gastric cancer who were treated in the Third People′s Hospital of Chengdu from March 2016 to April 2018 and 29 healthy volunteers who participated in the physical examination were selected. The serum levels of SALL4 were detected by ELISA. The expression of SALL4 in mRNA level and protein level in various gastric cancer cell lines and gastric mucosa cells were analyzed by Real-time PCR and Western blot respectively. The effects of SALL4 on the cell migration and invasion ability were analyzed by siRNA interference. The expression levels of related molecules of epithelial-mesenchymal transition (EMT) were detected by Western blot. Results The serum SALL4 levels in patients with gastric cancer were significantly higher than those in healthy volunteers, and the difference was highly statistically significant (P < 0.0001). The expression of SALL4 mRNA and protein in various gastric cancer cell lines was higher than that in gastric mucosal cell lines. The migration and invasion ability of gastric cancer cells were significantly decreased after interfering SALL4 expression, and the differences were statistically significant (P < 0.05). Decreased expression of SALL4 leaded to the up-regulation of E-cadherin expression and the down-regulation of snail, β-catenin and Wnt3a. Conclusion SALL4 is related to the progression of gastric cancer. It may promote cell migration and invasion by inducing the EMT process in gastric cancer cells.
刘蕾1 李砚2 郭元彪1. 胃癌患者血清SALL4的水平及其对胃癌细胞迁移能力的影响[J]. 中国医药导报, 2018, 15(29): 9-12,16.
LIU Lei1 LI Yan2 GUO Yuanbiao1. Serum level of SALL4 in gastric cancer patients and its effect on migration of gastric cancer cells. 中国医药导报, 2018, 15(29): 9-12,16.
[1] Rahman R，Asombang AW，Ibdah JA. Characteristics of gastric cancer in Asia [J]. World J Gastroenterol，2014，20（16）：4483-4490.
[2] D'Angelo G，Rienzo DT，Ojetti V. Microarray analysis in gastric cancer：a review [J]. World J Gastroenterol，2014， 20（34）：11 972-11 976.
[3] Kohlhase J，Schubert L，Liebers M，et al. Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes，including Okihiro syndrome，Holt-Oram syndrome，acro-renal-ocular syndrome，and patients previously reported to represent thalidomide embryopathy [J]. J Med Genet，2003，40（7）：473-478.
[4] 刘海荣，李岩.人类婆罗双树样基因-4研究进展[J].肿瘤研究与临床，2016，28（7）：497-501.
[5] Tatetsu H，Kong NR，Chong G，et al. SALL4，the missing link between stem cells，development and cancer [J]. Gene，2016，584（2）：111-119.
[6] Zhang J，Tam WL，Tong GQ，et al. SALL4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1 [J]. Nat Cell Biol，2006，8（10）：1114-1123.
[7] Yang J，Chai L，Fowles TC，et al. Genome-wide analysis reveals SALL4 to be a major regulator of pluripotency in murine-embryonic stem cells [J]. Proc Natl Acad Sci USA，2008，105（50）：19 756-19 761.
[8] Fujimoto M，Sumiyoshi S，Yoshizawa A，et al. SALL4 immunohistochemistry in non-small-cell lung carcinomas [J]. Histopathology，2014，64（2）：309-311.
[9] Yue X，Xiao L，Yang Y，et al. High cytoplasmic expression of SALL4 predicts a malignant phenotype and poor prognosis of breast invasive ductal carcinoma [J]. Neoplasma，2015，62（6）：980-988.
[10] Matsumoto Y，Itou J，Sato F，et al. SALL4-KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer [J]. Cancer Med，2018，7（2）：454-462.
[11] Li A，Jiao Y，Yong KJ，et al. SALL4 is a new target in endometrial cancer [J]. Oncogene，2015，34（1）：63-72.
[12] Liu L，Zhang J，Yang X，et al. SALL4 as an epithelial-mesenchymal transition and drug resistance inducer through the regulation of c-Myc in endometrial cancer [J]. PLoS One，2015，10（9）：e0138515.
[13] Khales SA，Abbaszadegan MR，Abdollahi A，et al. SALL4 as a new biomarker for early colorectal cancers [J]. J Cancer Res Clin Oncol，2015，141（2）：229-235.
[14] Zhang L，Xu Z，Xu X，et al. SALL4，a novel marker for human gastric carcinogenesis and metastasis [J]. Oncogene，2014，33（48）：5491-5500.
[15] Liu J，Wang L，Yang A，et al. Up-regulation of SALL4 associated with poor prognosis in gastric cancer [J]. Hepatogastroenterology，2014，61（133）：1459-1464.
[16] Yuan X，Zhang X，Zhang W，et al. SALL4 promotes gastric cancer progression through activating CD44 expression [J]. Oncogenesis，2016，5（11）：e268.
[17] Yong KJ，Gao C，Lim JS，et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma [J]. N Engl J Med，2013，368（24）：2266-2276.
[18] Zhang L，Yan Y，Jiang Y，et al. The expression of SALL4 in patients with gliomas：high level of SALL4 expression is correlated with poor outcome [J]. J Neurooncol，2015， 121（2）：261-268.
[19] Hao L，Zhao Y，Wang Z，et al. Expression and clinical significance of SALL4 and beta-catenin in colorectal cancer [J]. J Mol Histol，2016，47（2）：117-128.
[20] Itou J，Matsumoto Y，Yoshikawa K，et al. Sal-like 4 （SALL4） suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer [J]. FEBS Lett，2013，587（18）：3115-3121.
2018, Vol. 15 
京公网安备 11010502046598号